BioNTech SE/$BNTX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Ticker
$BNTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
6,772
ISIN
US09075V1026
Website
BioNTech SE Metrics
BasicAdvanced
$27B
-
-$3.76
1.28
-
Price and volume
Market cap
$27B
Beta
1.28
52-week high
$129.27
52-week low
$76.53
Average daily volume
1.1M
Financial strength
Current ratio
10.183
Quick ratio
9.864
Long term debt to equity
1.255
Total debt to equity
1.548
Interest coverage (TTM)
-80.81%
Profitability
EBITDA (TTM)
-1,197.577
Gross margin (TTM)
79.39%
Net profit margin (TTM)
-27.89%
Operating margin (TTM)
-46.49%
Effective tax rate (TTM)
3.20%
Revenue per employee (TTM)
$483,360
Management effectiveness
Return on assets (TTM)
-3.66%
Return on equity (TTM)
-3.94%
Valuation
Price to revenue (TTM)
8.037
Price to book
1.38
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
-18.56
Free cash flow yield (TTM)
-5.39%
Free cash flow per share (TTM)
-583.31%
Growth
Revenue change (TTM)
0.61%
Earnings per share change (TTM)
-786.52%
3-year revenue growth (CAGR)
-50.97%
3-year earnings per share growth (CAGR)
-59.88%
What the Analysts think about BioNTech SE
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
Bulls say / Bears say
BioNTech's partnership with Bristol Myers Squibb, involving a $1.5 billion upfront payment to co-develop the experimental cancer drug BNT327, signifies strong confidence in BioNTech's oncology pipeline and potential future revenue streams. (reuters.com)
The acquisition of Biotheus for $800 million grants BioNTech full global rights to BNT327/PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, enhancing its oncology portfolio and expanding its presence in the Chinese market. (stocktitan.net)
Analyst sentiment remains positive, with multiple 'Buy' ratings and an average 12-month price target of $131.75, indicating confidence in BioNTech's growth prospects. (markets.businessinsider.com)
BioNTech reported its first loss since 2020 due to a significant decline in COVID-19 vaccine demand, raising concerns about its ability to maintain profitability as pandemic-related revenues decrease. (bloomberg.com)
The FDA's appointment of Dr. Vinay Prasad, a known critic of COVID-19 policies, to head its Center for Biologics Evaluation and Research has introduced regulatory uncertainties that could impact BioNTech's vaccine approvals and market performance. (finviz.com)
BioNTech's Q3 2024 financial results showed a downgrade in COVID-19 vaccine revenue guidance, suggesting potential challenges in sustaining revenue levels as the pandemic subsides. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BioNTech SE Financial Performance
Revenues and expenses
BioNTech SE Earnings Performance
Company profitability
BioNTech SE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioNTech SE stock?
BioNTech SE (BNTX) has a market cap of $27B as of July 04, 2025.
What is the P/E ratio for BioNTech SE stock?
The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 0 as of July 04, 2025.
Does BioNTech SE stock pay dividends?
No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next BioNTech SE dividend payment date?
BioNTech SE (BNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioNTech SE?
BioNTech SE (BNTX) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.